It is no secret that the field of cancer genomics has grown rapidly over the past 5 to 10 years, and as many investigators already know, much of this growth can be attributed to the continued growth of next-generation sequencing (NGS) systems and their associated technologies. But, as with any scientific field, there is much work to be done.

 

The National Cancer Institute projected for the year 2018, approximately 1.7 million patients in the U.S. would be diagnosed with cancer and approximately 600,000 people  across the United States would lose their battle against cancer. Between 2012 and 2030, the Institute expects the number of newly diagnosed cancer cases across the world to increase by close to 60%, and historically, over half of new cancer cases world wide are reported in underdeveloped areas of Central America, Africa, and Asia.

 

How Can We Help?

As your NGS service provider, we are committed to offering all of our clients access to the industry's leading technology in cancer genomics. Not only are we able to make the latest sequencing platforms available to you; instruments such as the Illumina NovaSeq, PacBio Sequel, and the Ion S5 XL. We are also sure to stay up-to-date on the latest gene panels and sequencing methods offered by the industry's trusted names such as Illumina and Thermo Fisher Scientific. Below are a wide range of panels and services that we are able to collaborate with you on to make that next breakthrough in your cancer research.